{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+the+test+product",
    "query": {
      "intervention": "Vehicle of the test product"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 86,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+the+test+product&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T02:50:13.912Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03091777",
      "title": "Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Vaginosis"
      ],
      "interventions": [
        {
          "name": "GDC-229",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole Vaginal Gel 0.75%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Balmoral Medical company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 871,
      "start_date": "2017-03-10",
      "completion_date": "2018-03-27",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091777"
    },
    {
      "nct_id": "NCT02052752",
      "title": "A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Diseases"
      ],
      "interventions": [
        {
          "name": "3% Benzoyl Peroxide",
          "type": "DRUG"
        },
        {
          "name": "3% Benzoyl Peroxide Placebo",
          "type": "DRUG"
        },
        {
          "name": "Neutrogena Rapid Clear®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 90,
      "start_date": "2014-02",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-05-18",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052752"
    },
    {
      "nct_id": "NCT00483496",
      "title": "Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Solar Urticaria"
      ],
      "interventions": [
        {
          "name": "Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% alone (formula RV3131A-MV1211)",
          "type": "DRUG"
        },
        {
          "name": "bisoctrizole 10% alone (formula RV3131A-MV1237)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]",
          "type": "DRUG"
        },
        {
          "name": "V0096 CR vehicle (formula RV3131A-MV1197)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orfagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483496"
    },
    {
      "nct_id": "NCT03650361",
      "title": "Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Adapalene Gel 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Differin 0.3% Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "Adapalene Gel 0.3% Vehicle Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aleor Dermaceuticals Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 755,
      "start_date": "2018-09-17",
      "completion_date": "2019-02-16",
      "has_results": false,
      "last_update_posted_date": "2019-04-26",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 9,
      "location_summary": "Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650361"
    },
    {
      "nct_id": "NCT03499873",
      "title": "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac 0.3% Oph Susp",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac 0.3% Oph Susp (reference)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2018-03-28",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499873"
    },
    {
      "nct_id": "NCT01673659",
      "title": "A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Mometasone furoate",
          "type": "DRUG"
        },
        {
          "name": "Nasonex Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Padagis LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 1220,
      "start_date": "2012-08",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-22",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01673659"
    },
    {
      "nct_id": "NCT02618759",
      "title": "Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "DSXS",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2015-08-28",
      "completion_date": "2017-08-25",
      "has_results": true,
      "last_update_posted_date": "2018-12-10",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02618759"
    },
    {
      "nct_id": "NCT05763082",
      "title": "Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "roflumilast cream 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Zoryve",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Padagis LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 416,
      "start_date": "2023-02-07",
      "completion_date": "2023-08-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05763082"
    },
    {
      "nct_id": "NCT01703793",
      "title": "Safety and Efficacy Study in Subjects With Seborrheic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seborrheic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Test Product 49778",
          "type": "DRUG"
        },
        {
          "name": "Test Product 10156",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicis Global Service Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2012-09",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-09",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 22,
      "location_summary": "Fremont, California • Los Angeles, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703793"
    },
    {
      "nct_id": "NCT01430533",
      "title": "Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "azelaic acid pre foam formulation",
          "type": "DRUG"
        },
        {
          "name": "Vehicle pre foam formulation",
          "type": "DRUG"
        },
        {
          "name": "Water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 240,
      "start_date": "2011-09",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-09-29T02:50:13.912Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01430533"
    }
  ]
}